Stockreport

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Tango Therapeutics, Inc.  (TNGX) 
PDF – 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% –  – Combination studies with RAS(ON) in [Read more]